Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Danielle F Pinkiert, R.N.
CONTACT
Kathy L McGraw, Ph.D.
CONTACT
Lead
National Cancer Institute (NCI)
Background: * Myelodysplastic syndromes (MDS) are heterogeneous stem cell disorders characterized by ineffective hematopoiesis resulting in cellular dysplasia, peripheral cytopenias, and increased risk for transformation to acute myeloid leukemia (AML). * There are limited treatment options, all of which have unimpressive response rates and limited response durations, with the only potential cure being hematopoietic stem cell transplant (HSCT). Unfortunately, as a disease of the elderly (average age of diagnosis \>65 years), most participants are not eligible for HSCT due to advanced age and other comorbidities. * It is critical we further elucidate the processes that lead to disease manifestation to develop novel therapeutic strategies and alter the natural history of the disease. * In order to understand the biology of the disease, it is critical to have control biospecimens from healthy individuals to delineate the mechanisms driving disease pathogenesis. Objective: -To create a database of analyzed biospecimens collected from healthy volunteers. Eligibility: * Age \>= 18 years old * Healthy volunteers as confirmed by clinical evaluation Design: * This is a trial to analyze samples from healthy volunteers collected at NIH Clinical Center. --Participants = will be asked to provide blood, and/or bone marrow, and other samples (skin biopsy samples, saliva, stool samples). * The total protocol accrual goal is 1,000 participants. Enrollment is expected to take place over approximately 20-50 years.
Age
18–120
Sex
ALL
Healthy volunteers
Accepted
